REIMAGINING HEALTHCARE IN INDIA THROUGHBLENDED FINANCE

whitePaper | September 28, 2022

Specialty drugs span a wide range of disease states, from the more prevalent, yet complex, such as multiple sclerosis, to rare and orphan diseases, such as hereditary angioedema (HAE).

whitePaper | March 11, 2023

As innovation transforms the healthcare landscape, science and data are becoming the foundation for pharma to meet its obligations to patients and customers—and realize commercial opportunities.

whitePaper | September 26, 2022

As hospitals and private health offices nationwide slowly begin to emerge from the COVID-induced challenges posed over the last two years, there is a new understanding of, and necessity for, adaptable medical technology and practices.

whitePaper | May 20, 2022

Verifying provider credentials is a resource-intensive process that adds cost and time to the payor’s bottom line.

whitePaper | March 23, 2023

DCTs can take a variety of forms depending on patients’ needs, study protocol, drug company preferences, or regulatory requirements. Trials may be remote and decentralised from start to finish with no physical contact between participants and investigators or they may rely on hybrid designs that incorporate only certain elements of decentralisatio

whitePaper | February 24, 2023

To create the most realistic, patient-specific simulation for surgical training, vascular models must mimic how native tissue responds to pressure, punctures, and stitches.